Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Levofloxacin
- Accession Number
- DB01137 (APRD00477, DB06085)
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
- Structure
Structure for DB01137 (Levofloxacin)
- Synonyms
- (-)-Ofloxacin
- (3S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
- (S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
- (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
- (S)-Ofloxacin
- L-Ofloxacin
- Levofloxacin anhydrous
- Levofloxacine
- Levofloxacino
- Levofloxacinum
- Ofloxacin S-(-)-form
- External IDs
- MP-376
- Product Ingredients
Ingredient UNII CAS InChI Key Levofloxacin hemihydrate 6GNT3Y5LMF 138199-71-0 SUIQUYDRLGGZOL-RCWTXCDDSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Act Levofloxacin Tablet 250 mg Oral Teva 2009-06-24 Not applicable Canada 
Act Levofloxacin Tablet 750 mg Oral Teva 2009-06-24 Not applicable Canada Act Levofloxacin Tablet 500 mg Oral Teva 2009-06-24 Not applicable Canada Iquix Solution 15 mg/mL Ophthalmic Vistakon Pharmaceuticals 2004-06-01 2017-08-02 US 
Levaquin Tablet, film coated 500 mg/1 Oral Pd Rx Pharmaceuticals, Inc. 1996-12-20 Not applicable US Levaquin Tablet, film coated 750 mg/1 Oral Cardinal Health 1996-12-20 2017-12-22 US Levaquin Tablet, film coated 250 mg/1 Oral Red Pharm Drug, Inc. 1996-12-20 Not applicable US Levaquin Injection, solution 5 mg/mL Intravenous Janssen Pharmaceuticals 1996-12-20 2018-01-06 US Levaquin Tablet, film coated 750 mg/1 Oral Rebel Distributors 1996-12-20 Not applicable US Levaquin Tablet 250 mg Oral Janssen Pharmaceuticals 1997-11-28 2014-10-27 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Apo-levofloxacin Tablet 750 mg Oral Apotex Corporation 2009-06-24 Not applicable Canada Apo-levofloxacin Tablet 250 mg Oral Apotex Corporation 2009-06-24 Not applicable Canada Apo-levofloxacin Tablet 500 mg Oral Apotex Corporation 2009-06-24 Not applicable Canada Auro-levofloxacin Tablet 750 mg Oral Auro Pharma Inc 2016-04-12 Not applicable Canada Auro-levofloxacin Tablet 500 mg Oral Auro Pharma Inc 2016-04-12 Not applicable Canada Auro-levofloxacin Tablet 250 mg Oral Auro Pharma Inc 2016-04-12 Not applicable Canada Ava-levofloxacin Tablet 500 mg Oral Avanstra Inc 2011-09-15 2014-08-21 Canada Ava-levofloxacin Tablet 250 mg Oral Avanstra Inc 2011-09-15 2014-08-21 Canada Dom-levofloxacin Tablet 250 mg Oral Dominion Pharmacal Not applicable Not applicable Canada Dom-levofloxacin Tablet 750 mg Oral Dominion Pharmacal Not applicable Not applicable Canada - International/Other Brands
- Cravit / Elequine / Floxel / Leroxacin / Levokacin / Levox / Levoxacin / Mosardal / Nofaxin / Reskuin / Tavanic
- Categories
- Anti-Bacterial Agents
- Anti-Infective Agents
- Anti-Infective Agents, Urinary
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Antineoplastic Agents
- Chemically-Induced Disorders
- Combined Inhibitors of CYP3A4 and P-glycoprotein
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Enzyme Inhibitors
- Fluoroquinolones
- Moderate Risk QTc-Prolonging Agents
- OAT3 Substrates
- Ofloxacin
- P-glycoprotein/ABCB1 Inhibitors
- P-glycoprotein/ABCB1 Substrates
- QTc Prolonging Agents
- Quinolines
- Quinolone Antibacterials
- Quinolone Antimicrobial
- Quinolones
- Renal Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- UNII
- RIX4E89Y14
- CAS number
- 100986-85-4
- Weight
- Average: 361.3675
Monoisotopic: 361.143784348 - Chemical Formula
- C18H20FN3O4
- InChI Key
- GSDSWSVVBLHKDQ-JTQLQIEISA-N
- InChI
- InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
- IUPAC Name
- (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0⁵,¹³]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
- SMILES
- C[[email protected]]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1
Pharmacology
- Indication
For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.
- Structured Indications
- Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)
- Acute Pyelonephritis
- Acute maxillary sinusitis caused by M. catarrhalis
- Anthrax
- Bacterial Infections
- Cellulitis
- Chlamydial Infections
- Community Acquired Pneumonia (CAP)
- Complicated Urinary Tract Infections
- Conjunctivitis, Bacterial
- Cystic fibrosis pulmonary exacerbation caused by Pseudomonas aeruginosa
- Diverticulitis
- Epididymitis
- Furuncle
- Impetigo
- Infected animal bite
- Infection, Postoperative Wound
- Legionella Pneumophila Infections
- Plague
- Prostatitis caused by Proteus mirabilis
- Prosthetic Joint Infection
- Pyoderma
- Travelers' Diarrhea
- Tuberculosis
- Uncomplicated Urinary Tract Infections
- Urethritis
- Wound Infections
- Complicated Skin and subcutaneous tissue bacterial infection
- Hospital-acquired bacterial pneumonia
- Uncomplicated skin and subcutaneous tissue bacterial infections
- Pharmacodynamics
Levofloxacin, a fluoroquinolone antiinfective, is the optically active L-isomer of ofloxacin. Levofloxacin is used to treat bacterial conjunctivitis, sinusitis, chronic bronchitis, community-acquired pneumonia and pneumonia caused by penicillin-resistant strains of Streptococcus pneumoniae, skin and skin structure infections, complicated urinary tract infections and acute pyelonephritis.
- Mechanism of action
Levofloxacin inhibits bacterial type II topoisomerases, topoisomerase IV and DNA gyrase. Levofloxacin, like other fluoroquinolones, inhibits the A subunits of DNA gyrase, two subunits encoded by the gyrA gene. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing; DNA replication and transcription is inhibited.
Target Actions Organism ADNA topoisomerase 4 subunit A inhibitorHaemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) ADNA gyrase subunit A inhibitorHaemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) ADNA topoisomerase 2-alpha inhibitorHuman - Absorption
Absorption of ofloxacin after single or multiple doses of 200 to 400 mg is predictable, and the amount of drug absorbed increases proportionately with the dose.
- Volume of distribution
- Not Available
- Protein binding
24-38% (to plasma proteins)
- Metabolism
Mainly excreted as unchanged drug (87%); undergoes limited metabolism in humans.
- Route of elimination
Mainly excreted as unchanged drug in the urine.
- Half life
6-8 hours
- Clearance
- Not Available
- Toxicity
Side effects include disorientation, dizziness, drowsiness, hot and cold flashes, nausea, slurring of speech, swelling and numbness in the face
- Affected organisms
- Enteric bacteria and other eubacteria
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene (4R)-limonene may increase the neuroexcitatory activities of Levofloxacin. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Levofloxacin. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Levofloxacin. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when 5-androstenedione is combined with Levofloxacin. Experimental, Illicit Acarbose Levofloxacin may increase the hypoglycemic activities of Acarbose. Approved, Investigational Aceclofenac Aceclofenac may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Acemetacin Acemetacin may increase the neuroexcitatory activities of Levofloxacin. Approved, Experimental, Investigational Acenocoumarol Levofloxacin may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Levofloxacin. Approved Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Levofloxacin. Experimental Acetylsalicylic acid Acetylsalicylic acid may increase the neuroexcitatory activities of Levofloxacin. Approved, Vet Approved Adapalene Adapalene may increase the neuroexcitatory activities of Levofloxacin. Approved Afatinib The serum concentration of Afatinib can be increased when it is combined with Levofloxacin. Approved Albiglutide Levofloxacin may increase the hypoglycemic activities of Albiglutide. Approved Alclofenac Alclofenac may increase the neuroexcitatory activities of Levofloxacin. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Alclometasone is combined with Levofloxacin. Approved Aldosterone The risk or severity of adverse effects can be increased when Aldosterone is combined with Levofloxacin. Experimental, Investigational Alfuzosin Alfuzosin may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Almasilate Almasilate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental Alminoprofen Alminoprofen may increase the neuroexcitatory activities of Levofloxacin. Experimental Alogliptin Levofloxacin may increase the hypoglycemic activities of Alogliptin. Approved Aloglutamol Aloglutamol can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Aluminium Aluminium can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Aluminium acetoacetate Aluminium acetoacetate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Aluminium glycinate Aluminium glycinate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Amantadine Amantadine may increase the QTc-prolonging activities of Levofloxacin. Approved Ambroxol acefyllinate The metabolism of Ambroxol acefyllinate can be decreased when combined with Levofloxacin. Experimental, Investigational Amcinonide The risk or severity of adverse effects can be increased when Amcinonide is combined with Levofloxacin. Approved Aminophylline The metabolism of Aminophylline can be decreased when combined with Levofloxacin. Approved Amiodarone Levofloxacin may increase the QTc-prolonging activities of Amiodarone. Approved, Investigational Amitriptyline Amitriptyline may increase the QTc-prolonging activities of Levofloxacin. Approved Amoxapine Amoxapine may increase the QTc-prolonging activities of Levofloxacin. Approved Anagrelide Levofloxacin may increase the QTc-prolonging activities of Anagrelide. Approved Ancestim The risk or severity of cytotoxicity can be increased when Ancestim is combined with Levofloxacin. Approved, Investigational, Withdrawn Andrographolide Andrographolide may increase the neuroexcitatory activities of Levofloxacin. Investigational Androstenedione The risk or severity of adverse effects can be increased when Androstenedione is combined with Levofloxacin. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Anecortave is combined with Levofloxacin. Investigational anecortave acetate The risk or severity of adverse effects can be increased when anecortave acetate is combined with Levofloxacin. Investigational Anisodamine Anisodamine may increase the neuroexcitatory activities of Levofloxacin. Investigational Antipyrine Antipyrine may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Apalutamide The serum concentration of Levofloxacin can be decreased when it is combined with Apalutamide. Approved, Investigational Apocynin Apocynin may increase the neuroexcitatory activities of Levofloxacin. Investigational Apomorphine Apomorphine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Apremilast Apremilast may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Arformoterol Arformoterol may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Aripiprazole Aripiprazole may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Arsenic trioxide Levofloxacin may increase the QTc-prolonging activities of Arsenic trioxide. Approved, Investigational Artemether Levofloxacin may increase the QTc-prolonging activities of Artemether. Approved Asenapine Levofloxacin may increase the QTc-prolonging activities of Asenapine. Approved Asunaprevir The serum concentration of Asunaprevir can be increased when it is combined with Levofloxacin. Approved, Investigational, Withdrawn Atamestane The risk or severity of adverse effects can be increased when Atamestane is combined with Levofloxacin. Investigational Atazanavir Atazanavir may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Atomoxetine Atomoxetine may increase the QTc-prolonging activities of Levofloxacin. Approved Atorvastatin The risk or severity of adverse effects can be increased when Levofloxacin is combined with Atorvastatin. Approved Azapropazone Azapropazone may increase the neuroexcitatory activities of Levofloxacin. Withdrawn Azelastine Azelastine may increase the neuroexcitatory activities of Levofloxacin. Approved Azithromycin Azithromycin may increase the QTc-prolonging activities of Levofloxacin. Approved Balsalazide Balsalazide may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Levofloxacin. Investigational Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Levofloxacin. Approved, Investigational Bedaquiline Levofloxacin may increase the QTc-prolonging activities of Bedaquiline. Approved Bendazac Bendazac may increase the neuroexcitatory activities of Levofloxacin. Experimental Benorilate Benorilate may increase the neuroexcitatory activities of Levofloxacin. Experimental Benoxaprofen Benoxaprofen may increase the neuroexcitatory activities of Levofloxacin. Withdrawn Benzydamine Benzydamine may increase the neuroexcitatory activities of Levofloxacin. Approved Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Levofloxacin. Approved, Vet Approved Bevacizumab Bevacizumab may increase the cardiotoxic activities of Levofloxacin. Approved, Investigational Bevonium Bevonium may increase the neuroexcitatory activities of Levofloxacin. Experimental Bismuth Subcitrate Bismuth Subcitrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Bismuth subnitrate Bismuth subnitrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Bortezomib Bortezomib may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Levofloxacin. Approved Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Levofloxacin. Approved, Investigational Bromfenac Bromfenac may increase the neuroexcitatory activities of Levofloxacin. Approved Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Levofloxacin. Approved, Investigational Bucillamine Bucillamine may increase the neuroexcitatory activities of Levofloxacin. Investigational Budesonide The risk or severity of adverse effects can be increased when Budesonide is combined with Levofloxacin. Approved Bufexamac Bufexamac may increase the neuroexcitatory activities of Levofloxacin. Approved, Experimental Bumadizone Bumadizone may increase the neuroexcitatory activities of Levofloxacin. Experimental Buserelin Buserelin may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Levofloxacin. Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Levofloxacin. Approved Calcium Acetate Calcium Acetate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Calcium Carbonate Calcium Carbonate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Calcium Chloride Calcium Chloride can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium Citrate Calcium Citrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium glubionate Calcium glubionate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium Gluceptate Calcium Gluceptate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium gluconate Calcium gluconate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Calcium lactate Calcium lactate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Calcium lactate gluconate Calcium lactate gluconate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Calcium levulinate Calcium levulinate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental Calcium pangamate Calcium pangamate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Calcium Phosphate Calcium Phosphate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Calcium silicate Calcium silicate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Canagliflozin Levofloxacin may increase the hypoglycemic activities of Canagliflozin. Approved Carbaspirin calcium Carbaspirin calcium may increase the neuroexcitatory activities of Levofloxacin. Experimental, Investigational Carprofen Carprofen may increase the neuroexcitatory activities of Levofloxacin. Approved, Vet Approved, Withdrawn Casein Casein can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Castanospermine Castanospermine may increase the neuroexcitatory activities of Levofloxacin. Experimental Celecoxib Celecoxib may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Ceritinib Levofloxacin may increase the QTc-prolonging activities of Ceritinib. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Levofloxacin. Approved, Withdrawn Chloroquine Chloroquine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational, Vet Approved Chlorpromazine Chlorpromazine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational, Vet Approved Chlorpropamide Levofloxacin may increase the hypoglycemic activities of Chlorpropamide. Approved, Investigational Choline magnesium trisalicylate Choline magnesium trisalicylate may increase the neuroexcitatory activities of Levofloxacin. Approved Ciclesonide The risk or severity of adverse effects can be increased when Ciclesonide is combined with Levofloxacin. Approved, Investigational Ciprofloxacin Ciprofloxacin may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Cisapride Levofloxacin may increase the QTc-prolonging activities of Cisapride. Approved, Investigational, Withdrawn Citalopram Levofloxacin may increase the QTc-prolonging activities of Citalopram. Approved Clarithromycin Levofloxacin may increase the QTc-prolonging activities of Clarithromycin. Approved Clobetasol The risk or severity of adverse effects can be increased when Clobetasol is combined with Levofloxacin. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Levofloxacin. Approved Clobetasone The risk or severity of adverse effects can be increased when Clobetasone is combined with Levofloxacin. Approved Clocortolone The risk or severity of adverse effects can be increased when Clocortolone is combined with Levofloxacin. Approved Clomipramine Clomipramine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational, Vet Approved Clonixin Clonixin may increase the neuroexcitatory activities of Levofloxacin. Approved Clorindione Levofloxacin may increase the anticoagulant activities of Clorindione. Experimental Clozapine Clozapine may increase the QTc-prolonging activities of Levofloxacin. Approved Colchicine The serum concentration of Colchicine can be increased when it is combined with Levofloxacin. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Levofloxacin. Investigational Corticosterone The risk or severity of adverse effects can be increased when Corticosterone is combined with Levofloxacin. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Levofloxacin. Approved, Investigational Crizotinib Levofloxacin may increase the QTc-prolonging activities of Crizotinib. Approved Curcumin Curcumin may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Cyclophosphamide Cyclophosphamide may increase the cardiotoxic activities of Levofloxacin. Approved, Investigational Cymarin Cymarin may decrease the cardiotoxic activities of Levofloxacin. Experimental Dabigatran etexilate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Levofloxacin. Approved Dabrafenib Dabrafenib may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Dapagliflozin Levofloxacin may increase the hypoglycemic activities of Dapagliflozin. Approved Dasatinib Dasatinib may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Deflazacort The risk or severity of adverse effects can be increased when Deflazacort is combined with Levofloxacin. Approved, Investigational Degarelix Degarelix may increase the QTc-prolonging activities of Levofloxacin. Approved Delamanid Levofloxacin may increase the QTc-prolonging activities of Delamanid. Approved, Investigational Desflurane Desflurane may increase the QTc-prolonging activities of Levofloxacin. Approved Desipramine Desipramine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Deslanoside Deslanoside may decrease the cardiotoxic activities of Levofloxacin. Approved Desonide The risk or severity of adverse effects can be increased when Desonide is combined with Levofloxacin. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Levofloxacin. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Levofloxacin. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Levofloxacin. Experimental, Vet Approved Deutetrabenazine Levofloxacin may increase the QTc-prolonging activities of Deutetrabenazine. Approved, Investigational Dexamethasone The risk or severity of adverse effects can be increased when Dexamethasone is combined with Levofloxacin. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Levofloxacin. Vet Approved Diclofenac Diclofenac may increase the neuroexcitatory activities of Levofloxacin. Approved, Vet Approved Dicoumarol Levofloxacin may increase the anticoagulant activities of Dicoumarol. Approved Didanosine The serum concentration of Didanosine can be decreased when it is combined with Levofloxacin. Approved Difenpiramide Difenpiramide may increase the neuroexcitatory activities of Levofloxacin. Experimental Diflorasone The risk or severity of adverse effects can be increased when Diflorasone is combined with Levofloxacin. Approved Diflunisal Diflunisal may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when Difluocortolone is combined with Levofloxacin. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Difluprednate is combined with Levofloxacin. Approved Digitoxin Digitoxin may decrease the cardiotoxic activities of Levofloxacin. Approved, Investigational Digoxin Digoxin may decrease the cardiotoxic activities of Levofloxacin. Approved Digoxin Immune Fab (Ovine) Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Levofloxacin. Approved Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Levofloxacin. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Levofloxacin. Approved, Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Levofloxacin. Experimental Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Levofloxacin. Approved, Investigational Diphenadione Levofloxacin may increase the anticoagulant activities of Diphenadione. Experimental Diphenhydramine Diphenhydramine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Disopyramide Levofloxacin may increase the QTc-prolonging activities of Disopyramide. Approved Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Levofloxacin. Approved, Investigational Dofetilide Levofloxacin may increase the QTc-prolonging activities of Dofetilide. Approved, Investigational Dolasetron Dolasetron may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Domperidone Levofloxacin may increase the QTc-prolonging activities of Domperidone. Approved, Investigational, Vet Approved Doxepin Doxepin may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Levofloxacin. Approved, Investigational Dronedarone Levofloxacin may increase the QTc-prolonging activities of Dronedarone. Approved Droperidol Droperidol may increase the QTc-prolonging activities of Levofloxacin. Approved, Vet Approved Droxicam Droxicam may increase the neuroexcitatory activities of Levofloxacin. Withdrawn Dulaglutide Levofloxacin may increase the hypoglycemic activities of Dulaglutide. Approved, Investigational Duvelisib Duvelisib may increase the neuroexcitatory activities of Levofloxacin. Investigational Dyphylline The metabolism of Dyphylline can be decreased when combined with Levofloxacin. Approved E-6201 E-6201 may increase the neuroexcitatory activities of Levofloxacin. Investigational Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Levofloxacin. Approved Eliglustat Levofloxacin may increase the QTc-prolonging activities of Eliglustat. Approved Empagliflozin Levofloxacin may increase the hypoglycemic activities of Empagliflozin. Approved Epirizole Epirizole may increase the neuroexcitatory activities of Levofloxacin. Approved Equilenin The risk or severity of adverse effects can be increased when Equilenin is combined with Levofloxacin. Experimental Equilin The risk or severity of adverse effects can be increased when Equilin is combined with Levofloxacin. Approved Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Levofloxacin. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Levofloxacin. Approved Eribulin Eribulin may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Erythromycin Erythromycin may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational, Vet Approved Escitalopram Levofloxacin may increase the QTc-prolonging activities of Escitalopram. Approved, Investigational Estrone The risk or severity of adverse effects can be increased when Estrone is combined with Levofloxacin. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Levofloxacin. Approved Etanercept Etanercept may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Ethenzamide Ethenzamide may increase the neuroexcitatory activities of Levofloxacin. Experimental Ethyl biscoumacetate Levofloxacin may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etodolac Etodolac may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational, Vet Approved Etofenamate Etofenamate may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Etoricoxib Etoricoxib may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Evening primrose oil Evening primrose oil may increase the neuroexcitatory activities of Levofloxacin. Investigational, Nutraceutical Everolimus The serum concentration of Everolimus can be increased when it is combined with Levofloxacin. Approved Exenatide Levofloxacin may increase the hypoglycemic activities of Exenatide. Approved, Investigational Exisulind Exisulind may increase the neuroexcitatory activities of Levofloxacin. Investigational Ezogabine Ezogabine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Famotidine Famotidine may increase the QTc-prolonging activities of Levofloxacin. Approved Felbamate Felbamate may increase the QTc-prolonging activities of Levofloxacin. Approved Felbinac Felbinac may increase the neuroexcitatory activities of Levofloxacin. Experimental Fenbufen Fenbufen may increase the neuroexcitatory activities of Levofloxacin. Approved Fenoprofen Fenoprofen may increase the neuroexcitatory activities of Levofloxacin. Approved Fentiazac Fentiazac may increase the neuroexcitatory activities of Levofloxacin. Experimental Feprazone Feprazone may increase the neuroexcitatory activities of Levofloxacin. Experimental Ferric Carboxymaltose The serum concentration of Levofloxacin can be decreased when it is combined with Ferric Carboxymaltose. Approved Ferric pyrophosphate The serum concentration of Levofloxacin can be decreased when it is combined with Ferric pyrophosphate. Experimental Ferulic acid Ferulic acid may increase the neuroexcitatory activities of Levofloxacin. Experimental Fingolimod Fingolimod may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Flecainide Levofloxacin may increase the QTc-prolonging activities of Flecainide. Approved, Withdrawn Floctafenine Floctafenine may increase the neuroexcitatory activities of Levofloxacin. Approved, Withdrawn Fluasterone The risk or severity of adverse effects can be increased when Fluasterone is combined with Levofloxacin. Investigational Fluconazole Fluconazole may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Levofloxacin. Approved, Investigational Fluindione Levofloxacin may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumethasone The risk or severity of adverse effects can be increased when Flumethasone is combined with Levofloxacin. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Levofloxacin. Approved, Investigational Flunixin Flunixin may increase the neuroexcitatory activities of Levofloxacin. Vet Approved Flunoxaprofen Flunoxaprofen may increase the neuroexcitatory activities of Levofloxacin. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Levofloxacin. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Fluocinonide is combined with Levofloxacin. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Fluocortolone is combined with Levofloxacin. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Levofloxacin. Approved, Investigational Fluoxetine Levofloxacin may increase the QTc-prolonging activities of Fluoxetine. Approved, Vet Approved Flupentixol Levofloxacin may increase the QTc-prolonging activities of Flupentixol. Approved, Investigational, Withdrawn Fluprednidene The risk or severity of adverse effects can be increased when Fluprednidene is combined with Levofloxacin. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Fluprednisolone is combined with Levofloxacin. Approved Flurandrenolide The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Levofloxacin. Approved Flurbiprofen Flurbiprofen may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Levofloxacin. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Levofloxacin. Approved Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Levofloxacin. Approved Formestane The risk or severity of adverse effects can be increased when Formestane is combined with Levofloxacin. Approved, Investigational, Withdrawn Formoterol Formoterol may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Foscarnet Foscarnet may increase the QTc-prolonging activities of Levofloxacin. Approved Gadobenic acid Gadobenic acid may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Galantamine Galantamine may increase the QTc-prolonging activities of Levofloxacin. Approved Gemifloxacin Levofloxacin may increase the QTc-prolonging activities of Gemifloxacin. Approved, Investigational Gitoformate Gitoformate may decrease the cardiotoxic activities of Levofloxacin. Experimental Gliclazide Levofloxacin may increase the hypoglycemic activities of Gliclazide. Approved Glimepiride Levofloxacin may increase the hypoglycemic activities of Glimepiride. Approved Glipizide Levofloxacin may increase the hypoglycemic activities of Glipizide. Approved, Investigational Glyburide Levofloxacin may increase the hypoglycemic activities of Glyburide. Approved Goserelin Goserelin may increase the QTc-prolonging activities of Levofloxacin. Approved Granisetron Granisetron may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Guacetisal Guacetisal may increase the neuroexcitatory activities of Levofloxacin. Experimental Halcinonide The risk or severity of adverse effects can be increased when Halcinonide is combined with Levofloxacin. Approved, Investigational, Withdrawn Haloperidol Haloperidol may increase the QTc-prolonging activities of Levofloxacin. Approved HE3286 The risk or severity of adverse effects can be increased when HE3286 is combined with Levofloxacin. Investigational Higenamine Higenamine may increase the neuroexcitatory activities of Levofloxacin. Investigational Histrelin Histrelin may increase the QTc-prolonging activities of Levofloxacin. Approved Hydrocortisone The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Levofloxacin. Approved, Vet Approved Hydrotalcite Hydrotalcite can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental, Investigational Hydroxyzine Hydroxyzine may increase the QTc-prolonging activities of Levofloxacin. Approved Ibandronate Ibandronate may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Levofloxacin. Approved Ibuprofen Ibuprofen may increase the neuroexcitatory activities of Levofloxacin. Approved Ibuproxam Ibuproxam may increase the neuroexcitatory activities of Levofloxacin. Withdrawn Ibutilide Levofloxacin may increase the QTc-prolonging activities of Ibutilide. Approved Icatibant Icatibant may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Iloperidone Levofloxacin may increase the QTc-prolonging activities of Iloperidone. Approved Imidazole salicylate Imidazole salicylate may increase the neuroexcitatory activities of Levofloxacin. Experimental Imipramine Imipramine may increase the QTc-prolonging activities of Levofloxacin. Approved Indacaterol Indacaterol may increase the QTc-prolonging activities of Levofloxacin. Approved Indapamide Indapamide may increase the QTc-prolonging activities of Levofloxacin. Approved Indobufen Indobufen may increase the neuroexcitatory activities of Levofloxacin. Investigational Indomethacin Indomethacin may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Indoprofen Indoprofen may increase the neuroexcitatory activities of Levofloxacin. Withdrawn Insulin Aspart Levofloxacin may increase the hypoglycemic activities of Insulin Aspart. Approved Insulin Detemir Levofloxacin may increase the hypoglycemic activities of Insulin Detemir. Approved Insulin Glargine Levofloxacin may increase the hypoglycemic activities of Insulin Glargine. Approved Insulin Glulisine Levofloxacin may increase the hypoglycemic activities of Insulin Glulisine. Approved Insulin Human Levofloxacin may increase the hypoglycemic activities of Insulin Human. Approved, Investigational Insulin Lispro Levofloxacin may increase the hypoglycemic activities of Insulin Lispro. Approved Iron The serum concentration of Levofloxacin can be decreased when it is combined with Iron. Approved Iron Dextran The serum concentration of Levofloxacin can be decreased when it is combined with Iron Dextran. Approved, Vet Approved Iron saccharate The serum concentration of Levofloxacin can be decreased when it is combined with Iron saccharate. Approved Isavuconazole The serum concentration of Levofloxacin can be increased when it is combined with Isavuconazole. Approved, Investigational Isoflurane Isoflurane may increase the QTc-prolonging activities of Levofloxacin. Approved, Vet Approved Isoxicam Isoxicam may increase the neuroexcitatory activities of Levofloxacin. Withdrawn Isradipine Isradipine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Istaroxime The risk or severity of adverse effects can be increased when Istaroxime is combined with Levofloxacin. Investigational Itraconazole Itraconazole may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Ivabradine Ivabradine may increase the QTc-prolonging activities of Levofloxacin. Approved Kebuzone Kebuzone may increase the neuroexcitatory activities of Levofloxacin. Experimental Ketoconazole Ketoconazole may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Ketoprofen Ketoprofen may increase the neuroexcitatory activities of Levofloxacin. Approved, Vet Approved Ketorolac Ketorolac may increase the neuroexcitatory activities of Levofloxacin. Approved Lanatoside C Lanatoside C may decrease the cardiotoxic activities of Levofloxacin. Experimental Lanthanum carbonate The serum concentration of Levofloxacin can be decreased when it is combined with Lanthanum carbonate. Approved Lapatinib Lapatinib may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Levofloxacin. Approved Leflunomide Leflunomide may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Lenvatinib Levofloxacin may increase the QTc-prolonging activities of Lenvatinib. Approved, Investigational Leuprolide Leuprolide may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Liraglutide Levofloxacin may increase the hypoglycemic activities of Liraglutide. Approved Lisofylline Lisofylline may increase the neuroexcitatory activities of Levofloxacin. Investigational Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Levofloxacin. Approved, Investigational Lithium Lithium may increase the QTc-prolonging activities of Levofloxacin. Approved Lonazolac Lonazolac may increase the neuroexcitatory activities of Levofloxacin. Experimental Lopinavir Levofloxacin may increase the QTc-prolonging activities of Lopinavir. Approved Lornoxicam Lornoxicam may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Loteprednol The risk or severity of adverse effects can be increased when Loteprednol is combined with Levofloxacin. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Levofloxacin. Approved, Investigational Loxoprofen Loxoprofen may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Lumacaftor The serum concentration of Levofloxacin can be decreased when it is combined with Lumacaftor. Approved Lumefantrine Levofloxacin may increase the QTc-prolonging activities of Lumefantrine. Approved Lumiracoxib Lumiracoxib may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Levofloxacin. Illicit, Investigational, Withdrawn Macimorelin Levofloxacin may increase the QTc-prolonging activities of Macimorelin. Approved, Investigational Magaldrate Magaldrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Withdrawn Magnesium hydroxide Magnesium hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Magnesium oxide Magnesium oxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Magnesium peroxide Magnesium peroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Magnesium salicylate The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium salicylate. Approved Magnesium silicate Magnesium silicate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Magnesium sulfate The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate. Approved, Investigational, Vet Approved Magnesium Trisilicate Magnesium Trisilicate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Maprotiline Maprotiline may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Masoprocol Masoprocol may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when ME-609 is combined with Levofloxacin. Investigational Mecasermin Levofloxacin may increase the hypoglycemic activities of Mecasermin. Approved, Investigational Meclofenamic acid Meclofenamic acid may increase the neuroexcitatory activities of Levofloxacin. Approved, Vet Approved Medrysone The risk or severity of adverse effects can be increased when Medrysone is combined with Levofloxacin. Approved Mefenamic acid Mefenamic acid may increase the neuroexcitatory activities of Levofloxacin. Approved Mefloquine Mefloquine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Melengestrol The risk or severity of adverse effects can be increased when Melengestrol is combined with Levofloxacin. Vet Approved Meloxicam Meloxicam may increase the neuroexcitatory activities of Levofloxacin. Approved, Vet Approved Mesalazine Mesalazine may increase the neuroexcitatory activities of Levofloxacin. Approved Metamizole Metamizole may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational, Withdrawn Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Levofloxacin. Experimental Metformin Levofloxacin may increase the hypoglycemic activities of Metformin. Approved Methadone Methadone may increase the QTc-prolonging activities of Levofloxacin. Approved Methotrimeprazine Methotrimeprazine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Levofloxacin. Approved Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Levofloxacin. Approved, Vet Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Levofloxacin. Approved Metildigoxin Metildigoxin may decrease the cardiotoxic activities of Levofloxacin. Experimental Metoclopramide Metoclopramide may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Metronidazole Metronidazole may increase the QTc-prolonging activities of Levofloxacin. Approved Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Levofloxacin. Experimental Mifepristone Levofloxacin may increase the QTc-prolonging activities of Mifepristone. Approved, Investigational Miglitol Levofloxacin may increase the hypoglycemic activities of Miglitol. Approved Mirabegron Mirabegron may increase the QTc-prolonging activities of Levofloxacin. Approved Mirtazapine Mirtazapine may increase the QTc-prolonging activities of Levofloxacin. Approved Mizoribine Mizoribine may increase the neuroexcitatory activities of Levofloxacin. Investigational Moexipril Moexipril may increase the QTc-prolonging activities of Levofloxacin. Approved Mofebutazone Mofebutazone may increase the neuroexcitatory activities of Levofloxacin. Experimental Mometasone The risk or severity of adverse effects can be increased when Mometasone is combined with Levofloxacin. Approved, Vet Approved Moxifloxacin Moxifloxacin may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Mycophenolate mofetil Mycophenolate mofetil may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Mycophenolic acid The serum concentration of Mycophenolic acid can be decreased when it is combined with Levofloxacin. Approved Nabumetone Nabumetone may increase the neuroexcitatory activities of Levofloxacin. Approved Nafamostat Nafamostat may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Naftifine Naftifine may increase the neuroexcitatory activities of Levofloxacin. Approved Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Levofloxacin. Approved Naproxen Naproxen may increase the neuroexcitatory activities of Levofloxacin. Approved, Vet Approved Nateglinide Levofloxacin may increase the hypoglycemic activities of Nateglinide. Approved, Investigational NCX 1022 The risk or severity of adverse effects can be increased when NCX 1022 is combined with Levofloxacin. Investigational Nelfinavir Nelfinavir may increase the QTc-prolonging activities of Levofloxacin. Approved Nepafenac Nepafenac may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Nicardipine Nicardipine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Levofloxacin. Approved, Investigational Nifenazone Nifenazone may increase the neuroexcitatory activities of Levofloxacin. Experimental Niflumic Acid Niflumic Acid may increase the neuroexcitatory activities of Levofloxacin. Approved Nilotinib Levofloxacin may increase the QTc-prolonging activities of Nilotinib. Approved, Investigational Nimesulide Nimesulide may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational, Withdrawn Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Levofloxacin. Approved Nitroaspirin Nitroaspirin may increase the neuroexcitatory activities of Levofloxacin. Investigational Norfloxacin Norfloxacin may increase the QTc-prolonging activities of Levofloxacin. Approved Nortriptyline Nortriptyline may increase the QTc-prolonging activities of Levofloxacin. Approved Octreotide Octreotide may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Ofloxacin Levofloxacin may increase the QTc-prolonging activities of Ofloxacin. Approved Olanzapine Olanzapine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Oleandrin Oleandrin may decrease the cardiotoxic activities of Levofloxacin. Experimental, Investigational Oleoyl-estrone The risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Levofloxacin. Investigational Olodaterol Olodaterol may increase the QTc-prolonging activities of Levofloxacin. Approved Olopatadine Olopatadine may increase the neuroexcitatory activities of Levofloxacin. Approved Olsalazine Olsalazine may increase the neuroexcitatory activities of Levofloxacin. Approved Ondansetron Ondansetron may increase the QTc-prolonging activities of Levofloxacin. Approved Orgotein Orgotein may increase the neuroexcitatory activities of Levofloxacin. Vet Approved Ouabain Ouabain may decrease the cardiotoxic activities of Levofloxacin. Approved Oxaprozin Oxaprozin may increase the neuroexcitatory activities of Levofloxacin. Approved Oxyphenbutazone Oxyphenbutazone may increase the neuroexcitatory activities of Levofloxacin. Approved, Withdrawn Oxytocin Oxytocin may increase the QTc-prolonging activities of Levofloxacin. Approved, Vet Approved Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Levofloxacin. Approved, Vet Approved Paliperidone Levofloxacin may increase the QTc-prolonging activities of Paliperidone. Approved Panobinostat Levofloxacin may increase the QTc-prolonging activities of Panobinostat. Approved, Investigational Paramethasone The risk or severity of adverse effects can be increased when Paramethasone is combined with Levofloxacin. Approved Parecoxib Parecoxib may increase the neuroexcitatory activities of Levofloxacin. Approved Paroxetine Paroxetine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Parthenolide Parthenolide may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Pasireotide Pasireotide may increase the QTc-prolonging activities of Levofloxacin. Approved Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Levofloxacin. Approved Pentamidine Pentamidine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Perflutren Perflutren may increase the QTc-prolonging activities of Levofloxacin. Approved Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Levofloxacin. Approved, Investigational, Vet Approved, Withdrawn Peruvoside Peruvoside may decrease the cardiotoxic activities of Levofloxacin. Experimental Phenindione Levofloxacin may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Levofloxacin may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone Phenylbutazone may increase the neuroexcitatory activities of Levofloxacin. Approved, Vet Approved Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Levofloxacin. Approved Pimecrolimus Pimecrolimus may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Pimozide Levofloxacin may increase the QTc-prolonging activities of Pimozide. Approved Pioglitazone Levofloxacin may increase the hypoglycemic activities of Pioglitazone. Approved, Investigational Pirfenidone Pirfenidone may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Piroxicam Piroxicam may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Pirprofen Pirprofen may increase the neuroexcitatory activities of Levofloxacin. Experimental Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Levofloxacin. Approved Pitolisant The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Pitolisant. Approved, Investigational Posaconazole Posaconazole may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational, Vet Approved Pramlintide Levofloxacin may increase the hypoglycemic activities of Pramlintide. Approved, Investigational Pranoprofen Pranoprofen may increase the neuroexcitatory activities of Levofloxacin. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when Prasterone is combined with Levofloxacin. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Levofloxacin. Investigational Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Levofloxacin. Approved Prednicarbate The risk or severity of adverse effects can be increased when Prednicarbate is combined with Levofloxacin. Approved, Investigational Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Levofloxacin. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Levofloxacin. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Pregnenolone is combined with Levofloxacin. Approved, Experimental, Investigational Primaquine Primaquine may increase the QTc-prolonging activities of Levofloxacin. Approved Probenecid The serum concentration of Levofloxacin can be increased when it is combined with Probenecid. Approved, Investigational Procainamide Levofloxacin may increase the QTc-prolonging activities of Procainamide. Approved Proglumetacin Proglumetacin may increase the neuroexcitatory activities of Levofloxacin. Experimental Promazine Promazine may increase the QTc-prolonging activities of Levofloxacin. Approved, Vet Approved Promethazine Promethazine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Propacetamol Propacetamol may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Propafenone Levofloxacin may increase the QTc-prolonging activities of Propafenone. Approved Propofol Propofol may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational, Vet Approved Propyphenazone Propyphenazone may increase the neuroexcitatory activities of Levofloxacin. Experimental Proquazone Proquazone may increase the neuroexcitatory activities of Levofloxacin. Experimental Proscillaridin Proscillaridin may decrease the cardiotoxic activities of Levofloxacin. Experimental Protriptyline Protriptyline may increase the QTc-prolonging activities of Levofloxacin. Approved Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Levofloxacin. Approved PTC299 PTC299 may increase the neuroexcitatory activities of Levofloxacin. Investigational Quetiapine Levofloxacin may increase the QTc-prolonging activities of Quetiapine. Approved Quinapril Quinapril can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Quinidine Levofloxacin may increase the QTc-prolonging activities of Quinidine. Approved, Investigational Quinine Levofloxacin may increase the QTc-prolonging activities of Quinine. Approved Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Levofloxacin. Approved, Investigational Repaglinide Levofloxacin may increase the hypoglycemic activities of Repaglinide. Approved, Investigational Resveratrol Resveratrol may increase the neuroexcitatory activities of Levofloxacin. Approved, Experimental, Investigational Ribociclib The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Levofloxacin. Approved, Investigational Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Levofloxacin. Approved, Investigational Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Levofloxacin. Approved Rimexolone The risk or severity of adverse effects can be increased when Rimexolone is combined with Levofloxacin. Approved Risperidone Risperidone may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Ritonavir Ritonavir may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Rofecoxib Rofecoxib may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational, Withdrawn Rosiglitazone Levofloxacin may increase the hypoglycemic activities of Rosiglitazone. Approved, Investigational Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Levofloxacin. Approved Salbutamol Salbutamol may increase the QTc-prolonging activities of Levofloxacin. Approved, Vet Approved Salicylamide Salicylamide may increase the neuroexcitatory activities of Levofloxacin. Approved Salicylic acid Salicylic acid may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational, Vet Approved Salmeterol Salmeterol may increase the QTc-prolonging activities of Levofloxacin. Approved Salsalate Salsalate may increase the neuroexcitatory activities of Levofloxacin. Approved Saquinavir Levofloxacin may increase the QTc-prolonging activities of Saquinavir. Approved, Investigational Saxagliptin Levofloxacin may increase the hypoglycemic activities of Saxagliptin. Approved Semapimod Semapimod may increase the neuroexcitatory activities of Levofloxacin. Investigational Seratrodast Seratrodast may increase the neuroexcitatory activities of Levofloxacin. Approved Serrapeptase Serrapeptase may increase the neuroexcitatory activities of Levofloxacin. Investigational Sertraline Sertraline may increase the QTc-prolonging activities of Levofloxacin. Approved Sevelamer Sevelamer can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Sevoflurane Sevoflurane may increase the QTc-prolonging activities of Levofloxacin. Approved, Vet Approved Silodosin The serum concentration of Silodosin can be increased when it is combined with Levofloxacin. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Levofloxacin. Approved Sitagliptin Levofloxacin may increase the hypoglycemic activities of Sitagliptin. Approved, Investigational Sodium bicarbonate Sodium bicarbonate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Solifenacin Solifenacin may increase the QTc-prolonging activities of Levofloxacin. Approved Sorafenib Sorafenib may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Sotalol Levofloxacin may increase the QTc-prolonging activities of Sotalol. Approved SRT501 SRT501 may increase the neuroexcitatory activities of Levofloxacin. Investigational Strontium ranelate The serum concentration of Levofloxacin can be decreased when it is combined with Strontium ranelate. Approved, Withdrawn Sucralfate The serum concentration of Levofloxacin can be decreased when it is combined with Sucralfate. Approved Sulfadiazine Levofloxacin may increase the hypoglycemic activities of Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole Sulfamethoxazole may increase the QTc-prolonging activities of Levofloxacin. Approved Sulfasalazine Sulfasalazine may increase the neuroexcitatory activities of Levofloxacin. Approved Sulfisoxazole Sulfisoxazole may increase the QTc-prolonging activities of Levofloxacin. Approved, Vet Approved Sulindac Sulindac may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Sunitinib Sunitinib may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Suprofen Suprofen may increase the neuroexcitatory activities of Levofloxacin. Approved, Withdrawn Suxibuzone Suxibuzone may increase the neuroexcitatory activities of Levofloxacin. Experimental Tacrolimus Levofloxacin may increase the QTc-prolonging activities of Tacrolimus. Approved, Investigational Tamoxifen Tamoxifen may increase the QTc-prolonging activities of Levofloxacin. Approved Tarenflurbil Tarenflurbil may increase the neuroexcitatory activities of Levofloxacin. Investigational Telavancin Levofloxacin may increase the QTc-prolonging activities of Telavancin. Approved Telithromycin Telithromycin may increase the QTc-prolonging activities of Levofloxacin. Approved Tenidap Tenidap may increase the neuroexcitatory activities of Levofloxacin. Experimental Tenoxicam Tenoxicam may increase the neuroexcitatory activities of Levofloxacin. Approved Tepoxalin Tepoxalin may increase the neuroexcitatory activities of Levofloxacin. Vet Approved Terbutaline Terbutaline may increase the QTc-prolonging activities of Levofloxacin. Approved Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Levofloxacin. Experimental Teriflunomide The serum concentration of Levofloxacin can be increased when it is combined with Teriflunomide. Approved Tetrabenazine Levofloxacin may increase the QTc-prolonging activities of Tetrabenazine. Approved, Investigational Theophylline The metabolism of Theophylline can be decreased when combined with Levofloxacin. Approved Thioridazine Levofloxacin may increase the QTc-prolonging activities of Thioridazine. Approved, Withdrawn Thiothixene Thiothixene may increase the QTc-prolonging activities of Levofloxacin. Approved Tiaprofenic acid Tiaprofenic acid may increase the neuroexcitatory activities of Levofloxacin. Approved Tinoridine Tinoridine may increase the neuroexcitatory activities of Levofloxacin. Investigational Tioclomarol Levofloxacin may increase the anticoagulant activities of Tioclomarol. Experimental Tixocortol The risk or severity of adverse effects can be increased when Tixocortol is combined with Levofloxacin. Approved, Withdrawn Tizanidine Tizanidine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Tolazamide Levofloxacin may increase the hypoglycemic activities of Tolazamide. Approved, Investigational Tolbutamide Levofloxacin may increase the hypoglycemic activities of Tolbutamide. Approved, Investigational Tolfenamic Acid Tolfenamic Acid may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Tolmetin Tolmetin may increase the neuroexcitatory activities of Levofloxacin. Approved Tolterodine Tolterodine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Levofloxacin. Approved Topotecan The serum concentration of Topotecan can be increased when it is combined with Levofloxacin. Approved, Investigational Toremifene Levofloxacin may increase the QTc-prolonging activities of Toremifene. Approved, Investigational Tranilast Tranilast may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Trastuzumab Trastuzumab may increase the cardiotoxic activities of Levofloxacin. Approved, Investigational Trazodone Trazodone may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Treprostinil Treprostinil may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Levofloxacin. Approved, Vet Approved Tribenoside Tribenoside may increase the neuroexcitatory activities of Levofloxacin. Experimental Trimethoprim Trimethoprim may increase the QTc-prolonging activities of Levofloxacin. Approved, Vet Approved Trimipramine Trimipramine may increase the QTc-prolonging activities of Levofloxacin. Approved Triptolide Triptolide may increase the neuroexcitatory activities of Levofloxacin. Investigational Triptorelin Triptorelin may increase the QTc-prolonging activities of Levofloxacin. Approved, Vet Approved Tromethamine Tromethamine can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Ulobetasol The risk or severity of adverse effects can be increased when Ulobetasol is combined with Levofloxacin. Approved Valdecoxib Valdecoxib may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational, Withdrawn Vandetanib Levofloxacin may increase the QTc-prolonging activities of Vandetanib. Approved Vardenafil Vardenafil may increase the QTc-prolonging activities of Levofloxacin. Approved Varenicline The serum concentration of Varenicline can be increased when it is combined with Levofloxacin. Approved, Investigational Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Levofloxacin. Approved Venlafaxine Venlafaxine may increase the QTc-prolonging activities of Levofloxacin. Approved Vilanterol Vilanterol may increase the QTc-prolonging activities of Levofloxacin. Approved Vincristine The excretion of Vincristine can be decreased when combined with Levofloxacin. Approved, Investigational Voriconazole Voriconazole may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Vorinostat Vorinostat may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Warfarin Levofloxacin may increase the anticoagulant activities of Warfarin. Approved Zaltoprofen Zaltoprofen may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Zileuton Zileuton may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational, Withdrawn Ziprasidone Levofloxacin may increase the QTc-prolonging activities of Ziprasidone. Approved Zomepirac Zomepirac may increase the neuroexcitatory activities of Levofloxacin. Withdrawn Zuclopenthixol Levofloxacin may increase the QTc-prolonging activities of Zuclopenthixol. Approved, Investigational - Food Interactions
- Take without regard to meals. Take with water, drink lliberally. Taking this product with orange juice can result in reduced quinolone plasma levels.
References
- Synthesis Reference
Valerie Niddam-Hildesheim, "Preparation of levofloxacin and forms thereof." U.S. Patent US20030130507, issued July 10, 2003.
US20030130507- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0001929
- KEGG Drug
- D08120
- KEGG Compound
- C07660
- PubChem Compound
- 149096
- PubChem Substance
- 46505134
- ChemSpider
- 131410
- BindingDB
- 50366826
- ChEBI
- 63598
- ChEMBL
- CHEMBL33
- Therapeutic Targets Database
- DAP000160
- PharmGKB
- PA450214
- HET
- LFX
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Levofloxacin
- ATC Codes
- J01RA05 — Levofloxacin and ornidazole
- J01RA — Combinations of antibacterials
- J01R — COMBINATIONS OF ANTIBACTERIALS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- A02BD — Combinations for eradication of Helicobacter pylori
- A02B — DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
- A02 — DRUGS FOR ACID RELATED DISORDERS
- A — ALIMENTARY TRACT AND METABOLISM
- AHFS Codes
- 08:12.18 — Quinolones
- PDB Entries
- 3k9f / 3rae / 4juo / 4z2d / 5btg / 5bti / 5eix
- FDA label
- Download (139 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Advanced Pharmaceutical Services Inc.
- Apotheca Inc.
- A-S Medication Solutions LLC
- Atlantic Biologicals Corporation
- Cardinal Health
- Comprehensive Consultant Services Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- H.J. Harkins Co. Inc.
- Hospira Inc.
- Innoviant Pharmacy Inc.
- Janssen-Ortho Inc.
- Lake Erie Medical and Surgical Supply
- Letco Medical Inc.
- Liberty Pharmaceuticals
- McNeil Laboratories
- Medisca Inc.
- Murfreesboro Pharmaceutical Nursing Supply
- Neuman Distributors Inc.
- Nucare Pharmaceuticals Inc.
- OMJ Pharmaceuticals
- Ortho Mcneil Janssen Pharmaceutical Inc.
- Ortho-McNeil-Janssen Pharmaceuticals Inc.
- PD-Rx Pharmaceuticals Inc.
- Physicians Total Care Inc.
- Prepackage Specialists
- Rebel Distributors Corp.
- Redpharm Drug
- Remedy Repack
- Santen Inc.
- Southwood Pharmaceuticals
- Stat Rx Usa
- Teva Pharmaceutical Industries Ltd.
- Vistakon Pharmaceuticals LLC
- Yuhan Chemical Industrial Co. Ltd.
- Dosage forms
Form Route Strength Solution Ophthalmic 15 mg/mL Injection, solution Intravenous 5 mg/mL Solution Intravenous 25 mg Solution Intravenous 5 mg Injection Intravenous 25 mg/mL Injection Intravenous 5 mg/mL Injection, solution Intravenous 25 mg/mL Injection, solution Intravenous 250 mg/50mL Injection, solution Intravenous 500 mg/100mL Injection, solution Intravenous 750 mg/150mL Injection, solution, concentrate Intravenous 25 mg/mL Injection, solution, concentrate Intravenous 500 mg/20mL Injection, solution, concentrate Intravenous 750 mg/30mL Solution Oral 25 mg/mL Solution / drops Ophthalmic 5 mg/mL Solution / drops Topical 5 mg/mL Tablet Oral 250 mg/1 Tablet Oral 500 mg/1 Tablet Oral 750 mg/1 Tablet, film coated Oral 250 mg/1 Tablet, film coated Oral 500 mg/1 Tablet, film coated Oral 750 mg/1 Tablet Oral 250 mg Tablet Oral 500 mg Solution Respiratory (inhalation) 240 mg Solution Ophthalmic 5 mg/mL Tablet Oral 750 mg - Prices
Unit description Cost Unit Iquix 1.5% Solution 5ml Bottle 81.68USD bottle Levofloxacin hemihydr 100% powder 42.69USD g Levaquin 750 mg tablet 28.06USD each Levaquin 750 mg leva-pak tablet 27.51USD tablet Levaquin 500 mg tablet 16.57USD tablet Iquix 1.5% eye drops 15.71USD ml Levaquin 250 mg tablet 13.71USD tablet Quixin 0.5% eye drops 12.21USD ml Quixin 0.5% Solution 11.4USD ml Levaquin i.v. 25 mg/ml vial 1.94USD ml Levaquin 500 mg/100 ml d5w 0.44USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5053407 No 1993-12-20 2010-12-20 US US6806256 Yes 2002-08-26 2022-08-26 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility Insoluble Not Available logP 2.1 Not Available - Predicted Properties
Property Value Source Water Solubility 1.44 mg/mL ALOGPS logP -0.02 ALOGPS logP 0.65 ChemAxon logS -2.4 ALOGPS pKa (Strongest Acidic) 5.45 ChemAxon pKa (Strongest Basic) 6.2 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 7 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 73.32 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 94.94 m3·mol-1 ChemAxon Polarizability 36.69 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Quinoline carboxylic acids
- Direct Parent
- Quinoline carboxylic acids
- Alternative Parents
- Fluoroquinolones / N-arylpiperazines / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Benzoxazines / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / N-methylpiperazines show 15 more
- Substituents
- Quinoline-3-carboxylic acid / Fluoroquinolone / N-arylpiperazine / Aminoquinoline / Haloquinoline / Dihydroquinolone / Benzoxazine / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives show 34 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- quinolone antibiotic, fluoroquinolone antibiotic, ofloxacin (CHEBI:63598)
Targets
- Kind
- Protein
- Organism
- Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Dna topoisomerase type ii (atp-hydrolyzing) activity
- Specific Function
- Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
- Gene Name
- parC
- Uniprot ID
- P43702
- Uniprot Name
- DNA topoisomerase 4 subunit A
- Molecular Weight
- 83366.24 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Zheng X, Johnson C, Lu Y, Yanagihara R, Hollingshead S, Crain M, Benjamin W Jr, Waites KB: Clinical isolates of Streptococcus pneumoniae resistant to levofloxacin contain mutations in both gyrA and parC genes. Int J Antimicrob Agents. 2001 Oct;18(4):373-8. [PubMed:11691571]
- Schafer J, Hovde LB, Simonson D, Rotschafer JC: In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant. Diagn Microbiol Infect Dis. 2008 Feb;60(2):155-61. Epub 2007 Oct 29. [PubMed:17910998]
- Deryke CA, Du X, Nicolau DP: Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2006 Sep;58(3):601-9. Epub 2006 Jul 19. [PubMed:16857688]
- Kind
- Protein
- Organism
- Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Dna topoisomerase type ii (atp-hydrolyzing) activity
- Specific Function
- DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
- Gene Name
- gyrA
- Uniprot ID
- P43700
- Uniprot Name
- DNA gyrase subunit A
- Molecular Weight
- 97817.145 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Schmitz FJ, Hofmann B, Hansen B, Scheuring S, Luckefahr M, Klootwijk M, Verhoef J, Fluit A, Heinz HP, Kohrer K, Jones ME: Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1998 Apr;41(4):481-4. [PubMed:9598779]
- Brisse S, Milatovic D, Fluit AC, Verhoef J, Martin N, Scheuring S, Kohrer K, Schmitz FJ: Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins. Antimicrob Agents Chemother. 1999 Aug;43(8):2051-5. [PubMed:10428935]
- Messina C, Cafiso V, Campanile F, Santagati M, Stefani S: Rapid method for detection of gyrA and grlA mutations in unrelated strains of Staphylococci susceptible and resistant to levofloxacin. New Microbiol. 2001 Oct;24(4):347-53. [PubMed:11718372]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Ubiquitin binding
- Specific Function
- Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
- Gene Name
- TOP2A
- Uniprot ID
- P11388
- Uniprot Name
- DNA topoisomerase 2-alpha
- Molecular Weight
- 174383.88 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Bellon A, Perez-Garcia G, Coverdale JH, Chacko RC: Seizures associated with levofloxacin: case presentation and literature review. Eur J Clin Pharmacol. 2009 Oct;65(10):959-62. doi: 10.1007/s00228-009-0717-5. Epub 2009 Aug 26. [PubMed:19707748]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60. [PubMed:9262363]
- Yamaguchi H, Yano I, Hashimoto Y, Inui KI: Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2. J Pharmacol Exp Ther. 2000 Oct;295(1):360-6. [PubMed:10992002]
- Yamaguchi H, Yano I, Saito H, Inui K: Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm Res. 2004 Feb;21(2):330-8. [PubMed:15032316]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
- Gene Name
- SLC22A6
- Uniprot ID
- Q4U2R8
- Uniprot Name
- Solute carrier family 22 member 6
- Molecular Weight
- 61815.78 Da
References
- Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K: Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett. 1998 Nov 6;438(3):321-4. [PubMed:9827570]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Quaternary ammonium group transmembrane transporter activity
- Specific Function
- Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
- Gene Name
- SLC22A2
- Uniprot ID
- O15244
- Uniprot Name
- Solute carrier family 22 member 2
- Molecular Weight
- 62579.99 Da
References
- Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. [PubMed:12089365]
- Okuda M, Urakami Y, Saito H, Inui K: Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31. [PubMed:10082798]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Symporter activity
- Specific Function
- Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
- Gene Name
- SLC22A4
- Uniprot ID
- Q9H015
- Uniprot Name
- Solute carrier family 22 member 4
- Molecular Weight
- 62154.48 Da
References
- Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651]
Drug created on June 13, 2005 07:24 / Updated on May 22, 2018 23:49